EyePoint (EYPT) Asset Utilization Ratio (2011 - 2026)
EyePoint (EYPT) posted Asset Utilization Ratio of 0.02 for Q1 2026, down 77.09% sequentially from 0.1 in Q4 2025, and down 83.73% YoY from 0.14 in Q1 2025.
EyePoint (EYPT) Asset Utilization Ratio (2011 - 2026) Analysis & Trends
EyePoint has reported Asset Utilization Ratio for 16 years, with the latest figure at 0.02 in Q1 2026.
- Quarterly Asset Utilization Ratio fell 83.73% year-over-year to 0.02 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.02 (down 83.73% YoY) and the FY2025 annual result came in at 0.08, down 28.32% from the prior year.
- Asset Utilization Ratio fell to 0.02 in Q1 2026 per EYPT's latest filing, from 0.1 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.25 in Q3 2023 and troughed at 0.02 in Q1 2026.
- A 5-year average of 0.16 and a median of 0.15 in 2024 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2023 and 2026: Asset Utilization Ratio surged 55.08% in 2023, then slumped 83.73% in 2026.
- Over 5 years, Asset Utilization Ratio stood at 0.21 in 2022, then decreased by 13.53% to 0.18 in 2023, then plunged by 32.65% to 0.12 in 2024, then fell by 15.29% to 0.1 in 2025, then slumped by 77.09% to 0.02 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.02, 0.1, and 0.15 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 0.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.01 |
| Mar 31, 2026 | 0.02 |
| Dec 31, 2025 | 0.10 |
| Sep 30, 2025 | 0.15 |
| Jun 30, 2025 | 0.16 |
| Mar 31, 2025 | 0.14 |
| Dec 31, 2024 | 0.12 |
| Sep 30, 2024 | 0.15 |
| Jun 30, 2024 | 0.15 |
| Mar 31, 2024 | 0.15 |
| Dec 31, 2023 | 0.18 |
| Sep 30, 2023 | 0.25 |
| Jun 30, 2023 | 0.23 |
| Mar 31, 2023 | 0.24 |
| Dec 31, 2022 | 0.21 |
| Sep 30, 2022 | 0.19 |
| Jun 30, 2022 | 0.17 |
| Mar 31, 2022 | 0.15 |
| Dec 31, 2021 | 0.17 |
| Sep 30, 2021 | 0.19 |